Latest Content

The ACCESS Model signals a shift toward outcome-aligned payments and a necessary reframing of what “value” actually means.

At the 6-year mark, CheckMate 9LA reveals significant long-term survival benefits for metastatic non-small cell lung cancer patients using dual immunotherapy with nivolumab and ipilimumab. These data were featured in the 2025 Year in Review in Non-Small Cell Lung Cancer.

Researchers unveil a spatial multi-omics atlas revealing immune cell interactions and lipid metabolism's role in metabolic liver diseases, offering new therapeutic insights.

New York City nurses continue their strike over staffing, safety, and benefits through negotiations on day 5 of the city’s largest nursing strike.

France approved botensilimab plus balstilimab for select ovarian cancers and soft tissue sarcomas, expanding early access to this dual immunotherapy.

In this week’s health equity news, ICHRAs may offer flexible health coverage options amid ACA subsidy uncertainties, and advocates rally for mental health funding stability.

Richter transformation with CNS involvement in CLL presents a poor prognosis, highlighting the need for tailored treatment strategies and further research.

FDA granted breakthrough therapy designation to pemvidutide based on its potential in treating metabolic dysfunction–associated steatohepatitis (MASH).

Jose Guzman Garcia, PharmD, MHA, BCCCP, discusses key pharmacy initiatives at UC Davis Health.